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Abstract
Background: Herb-drug interactions are an important issue in drug safety and clinical practice. The aim of this
epidemiological study was to characterize associations of clinical outcomes with concomitant herbal and antipsychotic use
in patients with schizophrenia.
Methods and Findings: In this retrospective, cross-sectional study, 1795 patients with schizophrenia who were randomly
selected from 17 psychiatric hospitals in China were interviewed face-to-face using a structured questionnaire. Association
analyses were conducted to examine correlates between Chinese medicine (CM) use and demographic, clinical variables,
antipsychotic medication mode, and clinical outcomes. The prevalence of concomitant CM and antipsychotic treatment was
36.4% [95% confidence interval (95% CI) 34.2%–38.6%]. Patients using concomitant CM had a significantly greater chance of
improved outcomes than non-CM use (61.1% vs. 34.3%, OR= 3.44, 95% CI 2.80–4.24). However, a small but significant
number of patients treated concomitantly with CM had a greater risk of developing worse outcomes (7.2% vs. 4.4%,
OR= 2.06, 95% CI 2.06–4.83). Significant predictors for concomitant CM treatment-associated outcomes were residence in
urban areas, paranoid psychosis, and exceeding 3 months of CM use. Herbal medicine regimens containing Radix Bupleuri,
Fructus Gardenia, Fructus Schisandrae, Radix Rehmanniae, Akebia Caulis, and Semen Plantaginis in concomitant use with
quetiapine, clozapine, and olanzepine were associated with nearly 60% of the risk of adverse outcomes.
Conclusions: Concomitant herbal and antipsychotic treatment could produce either beneficial or adverse clinical effects in
schizophrenic population. Potential herb-drug pharmacokinetic interactions need to be further evaluated.
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Introduction
With the widespread use of various herbal products which are
often concomitantly used with pharmaceutical drugs, herb-drug
interactions have become an important issue in drug safety and
clinical practice [1,2]. This was initially because of several case
studies reporting nephrotoxic and hepatotoxic effects associated
with herbal medicine use [3–5]. It is well documented that
concomitant use of herbal medicine with conventional drug
treatment can alter pharmacokinetic profiles of many classes of
pharmaceutical drugs, including psychotropic agents, anticoagu-
lants, oral contraceptives, immunosuppressants, cardiovascular
drugs, anti-HIV, anticancer agents and antiepileptics [1,2,6].
However, whether such concomitant treatment with herbal and
conventional medicine is associated with clinical outcomes in a
defined population of patients remains to be determined.
Most patients with schizophrenia may develop a chronic course
and are required for long-term maintenance treatment [7].
Although antipsychotic therapy is a mainstay in the maintenance
treatment of schizophrenia, patients still often experience relapse
and various adverse events caused by antipsychotic treatment [7].
In order to improve the therapeutic efficacy and reduce adverse
side effects related to antipsychotic therapy, herbal medicine and
other alternative therapies have been increasingly introduced into
the treatment of schizophrenia [8]. This is particularly apparent in
Chinese patients who have distinctive perceptions of Chinese
medicine (CM), of which herbal materials account for about 85%
preparations and products.
Numerous studies have shown therapeutic benefits of herbal
medicine for persistent negative symptoms, cognitive impairment,
and adverse side effects in schizophrenic patients [8]. Our recent
study revealed that herbal medicine could alleviate hyperprolac-
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tinemia in schizophrenic patients [9]. Nevertheless, there are also
case studies reporting acute and persistent psychosis caused by
herbal supplementary use [10,11]. These data suggest that herbal
medicine in combination with antipsychotic drugs may produce
either positive or negative clinical effects, making it important to
examine potential relationships between clinical outcomes and
concomitant treatment with herbal and antipsychotic agents in
schizophrenia.
The primary objective of this epidemiological survey was to
determine the prevalence of CM concomitant use and its
associations with demographic, clinical characteristics and treat-
ment outcomes in a random sample of patients with schizophrenia
through face-to-face interview using a structured questionnaire.
Methods
Study design and setting
This retrospective, cross-sectional epidemiological study was
conducted in 17 psychiatric hospitals and mental health centers in
China. The selection of the study sites was based on geographic
and sociodemographic variations as previously described [12],
with particular consideration of regions, local economic develop-
ment levels, and overall educational levels, as these variables are
heavily related to perceptions and beliefs for CM. The study was
approved by Institutional Review Board (IRB) of the University of
Hong Kong/Hospital Authority Hong Kong West Cluster and
registered at www.HKClinicalTrials.com (HKCTR-874). All
participants or their guardians were required to give written
informed consent for participating in the survey. The survey was
conducted between April 2009 and September 2009.
Population and sample
The study population was confined to patients with schizophre-
nia who visited psychiatric clinics or were hospitalized during the
survey period. Patients who met the following criteria were eligible
for the study: (1) aged 15 years or above; (2) had a primary
diagnosis of schizophrenia or schizoaffective disorder based on
International Classification of Diseases (ICD), 10th Edition [13]; (3) had
been taking conventional antipsychotic treatment for at least 6
weeks; and (4) patients, their caregivers and/or doctors could
provide necessary information about CM use if CM was used.
One key question that the present study attempted to answer
was whether concomitant use of CM could affect the clinical
outcomes of patients with schizophrenia, particularly adverse
outcomes related to concomitant CM and antipsychotic use.
Estimation of sample size was therefore based on the prevalence of
CM use and the proportion of CM users with worse outcomes (see
below). These two indices had been obtained from a pilot survey of
297 patients with schizophrenia [8], showing that nearly 36% of
patients concomitantly used CM and 5.7% of CM users
experienced worse outcomes, while only 2.8% of non-CM users
had worse outcomes. In order to detect a 2.9% difference in the
rate of worse outcomes between CM users and non-CM users,
with a power (1-b) of 80% and a two-tailed level of a =0.05, 1750
participants were required to detect statistical difference in terms
of worse outcomes associated with concomitant CM use. The
number of surveyed subjects allocated to each study site was
determined based on the volume of visits and annual admission
numbers. The selection of eligible patients at each survey site was
determined using random number tables.
Study instruments
A specifically designed structured questionnaire was adminis-
tered in the survey. The questionnaire covered: (1) sociodemo-
graphic and clinical characteristics; (2) purpose, advice source,
attitude, and awareness of CM use; (3) the concomitant use pattern
including individual CMs, conventional medication modes, and
duration of the concomitant use; and (4) clinical outcomes.
Chinese medicine (CM) is defined as preparations and products in
powder, tablet, capsule, soft-gel, or liquid form prepared from
single or mixed herbal, mineral, and animal materials or extracts
[8]. CM users were defined as those who had been using CM
consecutively for at least one month or cumulatively for at least 3
months with no more than 45 days of absence in total and no more
than 7 consecutive days of absence when the survey was
conducted. Those who never or only occasionally used CM were
defined as non-CM users. This definition of the length of CM use
was based on CM clinical practice, demonstrating that CM
therapy of most chronic mental-emotional conditions requires a
considerable period before observable improvements are achieved
[14].
Clinical outcomes were classified as improved, worse, and
unchanged condition. Improved outcomes were defined as
clinically meaningful improvements occurring in the preceding
one month on one or more conditions as follows: (1) psychosis; (2)
comorbid psychiatric symptoms, mainly anxiety, depression,
cognitive impairment, and sleep disorders; (3) adverse side effects
associated with antipsychotic therapy, frequently body weight
gain, constipation, enuresis, hyperprolactinemia, hypersalivation,
leukopenia, and tardive dyskinesia; and (4) comorbid non-
psychiatric conditions, such as hypertension and diabetes. Worse
outcomes were defined as hospitalization, emergency room visits,
or changes in medication modes due to the worsening of psychosis,
comorbid symptoms, intolerable side effects, or the occurrence of
new comorbid symptoms in the preceding one month. Patients
who did not experience either clinically meaningful improvement
or worsening in the preceding one month were defined as subjects
with unchanged conditions. The assessment of clinical outcomes
was conducted by psychiatrists based on changes in the severity
and frequency of episodes of related symptoms, physical
examination, and laboratory tests as well as reports from patients
and their guardians.
Survey procedures
The survey was performed by trained psychiatrists on site with
face-to-face interview. To ensure consistency of the survey across
sites and over time, two sessions of training workshop were
conducted for interviewers who were practicing psychiatry. Upon
completion of the training workshops, inter-rater reliability was
assessed by calculating interrater agreement coefficients (k value)
for the designed questionnaire. All interviewers had achieved a k
value of at least 0.8 after training sessions. In addition, post-survey
interviews were further conducted to verify missing and illogical
data.
Data analysis
The prevalence of CM use was calculated using maximum
likelihood estimation of logistic regression. Chi-square (x2) test was
used to determine bivariate associations between CM use and
demographic and clinical variables. Binary logistic regression
model was further used for multivariate analyses to identify
independent factors associated with CM use from the same
variable tested in the bivariate analysis. The association between
clinical outcomes and CM use was also examined using Chi-
square (x2) test and binary logistic regression analysis, with
adjustment for demographic and clinical variables that were found
to be significantly associated with CM use.
Concomitant Use of Herbal and Antipsychotic Agents
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Subgroup analyses were conducted in CM-using subjects to
further determine associations between clinical outcomes and CM
and antipsychotic concomitant use modes. Chi-square test and
multinomial logistic regression model were respectively utilized to
examine bivariate and multivariate associations of clinical
outcomes with demographic and clinical variables. Multinomial
logistic regression model was also applied to evaluate associations
of clinical outcomes with individual CMs and antipsychotic
regimens that were used in at least 5% of CM-using respondents
with either improved or worsened conditions, with adjustment for
demographic and clinical variables that were shown to be
significantly associated with clinical outcomes.
Odds ratio (OR) and 95% confidence interval (95% CI) were
obtained from binary and multinomial logistic regression analysis.
In association analyses of clinical outcomes, the unchanged
outcome served as reference for improved and worse outcome in
the calculation of OR values. All analyses were performed with
SPSS version 16 software (Chicago, IL, USA). Statistical
significance was defined as p,0.05 and all tests were two-sided.
Results
The characteristics of the sample
In a total of 1795 eligible subjects surveyed, seven were
excluded from the analyses due to missing basic demographic and
clinical data (gender, age, and the illness duration). In the
remaining 1788 subjects who were included in the final analyses,
51% were males and the mean (6SD) age was 32612 years. Fifty-
three percent were diagnosed with paranoid schizophrenia. These
demographic and clinical characteristics were similar to those
reported in previous epidemiological surveys of schizophrenic
population in China [15].
The characteristics of antipsychotic medication modes
Thirty-five psychotropic drugs were identified. Medication
regimens of 99.3% subjects included antipsychotics and 43%
had two or more antipsychotics. The remaining 0.7% subjects
were medicated with mood stabilizers occasionally combined with
antipsychotics. The most commonly used antipsychotics in all
subjects were risperidone (50.8%), quetiapine (21.0%), clozapine
(17.2%), olanzapine (8.2%), and phenothiazines (7.0%). This
medication mode was similar to that previously reported in China
[16]. No significant differences were observed in frequency
distribution of these antipsychotic regimens between CM- and
non-CM-using subjects (see below), except for risperidone
monotherapy. For the latter the proportion of CM-using
respondents treated was significantly higher than non-CM-using
respondents (30.8% vs. 23.4%, p,0.001, Chi-square test).
The prevalence and characteristics of CM use
Direct observation showed a prevalence of 37.5% (671/1788) of
the concomitant use. Re-calculation using maximum likelihood
estimation yielded a similar prevalence of 36.4% (95% CI: 34.2%–
38.6%). One hundred and twenty different CM materials used
were identified: 92 herbal materials, 12 mineral materials, and 16
animal materials. But 33.7% of CM-using subjects were unable to
provide full information about their CM formulae or prescriptions
for identifying individual CMs. Only a small portion (6.4%, 43/
671) of CM-using patients used single-herbal preparations.
There were 86% of CM-users who used CM therapy initially in
order to enhance antipsychotic efficacy, reduce antipsychotic-
induced adverse side effects and comorbid psychiatric symptoms
(mainly anxiety, depression, cognitive and sleep problems). Sixty-
six percent of CM users reported that CM use was recommended
by their psychiatrists. Most CMs were prescribed by CM
practitioners. Nearly 47% of CM-users were entirely unaware of
potential risks of concomitant use of herbal and antipsychotic
agents; only 16.4% realized such potential risks. In non-CM-using
patients, 35.1% did not know much about CM and 58.1% did not
think CM was helpful for their conditions, while only 5.1% were
aware of the potential risks of the concomitant treatment.
Demographic and clinical correlates of CM use
Bivariate analysis displayed significant associations of CM use
with gender (p = 0.002), household income (p = 0.001), the illness
duration (p,0.001), number of episode (p,0.001), and number of
hospitalization (p,0.001) (Table 1). Multivariate analysis further
revealed that CM use was significantly associated with male
(OR=1.32, 95% CI 1.09-1.62, p = 0.006), residence in rural areas
(OR=1.48, 95% CI 1.18–1.85, p = 0.001), average (OR=1.56,
95% CI 1.19–2.06, p = 0.001) and high (OR=2.36, 95% CI 1.58–
3.53, p,0.001) household income, and greater than one year of
illness duration (OR=1.95, 95% CI 1.45–2.63, p,0.001).
CM use correlates of clinical outcomes
While 61.1% (410/671) of CM-using patients and 34.3% (383/
1117) of non-CM-using patients displayed improved outcomes,
7.2% (48/671) CM users and 4.4% (49/1117) of non-CM users
experienced worse outcomes in the preceding one month (Table 2).
Chi-square tests showed that clinical outcomes were significantly
associated with whether CM was concomitantly used with
antipsychotic drugs (p,0.001). In a binary logistic regression
model, CM users had significantly greater odds of improved
(OR=3.44, 95% CI 2.80–4.24, p,0.001) and worse outcomes
(OR=3.15, 95% CI 2.06–4.83, p,0.001) compared to non-CM
users.
Demographic and clinical correlates of clinical outcomes
in CM users
Chi-square tests showed that clinical outcomes were significantly
associated with resident areas (p,0.001), diagnostic types (p,0.001),
and duration of CM use (p=0.007). Multinomial logistic regression
analysis further revealed significant associations of improved
outcomes with residence in urban areas (OR=4.81, 95% CI 3.14–
7.36, p,0.001), paranoid schizophrenia (OR=2.65, 95% CI 1.83–
3.84, p,0.001) andmore than 3months of CM use (OR=1.35, 95%
CI 0.91–1.98, p=0.036). In CM users who experienced worse
conditions, similar significant multivariate associations were also
observed with residence in urban areas (OR=6.91, 95% CI 3.09–
15.43, p,0.001), paranoid schizophrenia (OR=1.89, 95% CI 0.96–
3.71, p=0.012), and more than 3 months of CM use (OR=3.28,
95% CI 1.44–7.46, p=0.005) (Table 3).
Antipsychotic medication correlates of clinical outcomes
in CM users
Five different antipsychotic agents and five antipsychotic
treatment regimens that were used in at least 5% of CM-using
patients with either improved or worse outcomes were identified
(Table 4). Multinomial logistical regression analyses, with
adjustment for resident areas, diagnostic types, and duration of
CM use, variables that were significantly associated with clinical
outcomes, revealed no significant associations with any antipsy-
chotic treatment regimens favoring improve outcomes, but
significantly lower odds of improved outcomes were observed in
patients whose antipsychotic regimens included olanzapine
(OR=0.48, 95% CI 0.27–0.85, p = 0.035). There were signifi-
cantly higher odds of worse outcomes in subjects whose
Concomitant Use of Herbal and Antipsychotic Agents
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antipsychotic regimens included quetiapine (OR=1.90, 95% CI
0.88–4.08, p = 0.013), quetiapine alone (OR=2.16, 95% CI 0.95–
4.95, p = 0.031) or clozapine alone (OR=3.02, 95% CI 0.94–
9.70, p = 0.025) (Table 4).
Individual CM correlates of clinical outcomes
Of 120 different CM materials identified, 21 (20 herbal
materials and one animal material) were used in at least 5% of
CM-using subjects with either improved or worse outcomes
(Table 5). Multinomial logistic regression model analysis showed
no significant associations of improved outcomes with any
individual CMs identified, but the inclusion of Acorus gramineus
in CM treatment regimens significantly reduced odds of worse
outcomes compared to improved outcomes (OR=0.11, 95% CI
0.01–0.88, p = 0.037). Significantly higher odds of worse outcomes
were observed in subjects whose CM treatment regimens included
Radix Bupleuri (OR=2.49, 95% CI 1.10–5.62, p = 0.028),
Fructus Gardenia (OR=9.16, 95% CI 4.19–20.02, p,0.001),
Fructus Schisandrae (OR=3.90, 95% CI 1.42–10.73, P = 0.008),
Radix Rehmanniae (OR=3.48, 95% CI 1.03–11.70, p = 0.044),
Akebia Caulis (OR=14.6, 95% CI 2.50–31.87, p,0.001), and
Semen Plantaginis (OR=21.10, 95% CI 4.32–103.05, p,0.001).
Frequency distributions revealed that concomitant treatment
regimens containing these six herbal materials and worse
outcome-associated antipsychotics accounted for 59.8% (49/82)
of total identified concomitant treatment regimens in patients with
worse outcomes (Table 6).
Discussion
In our survey of a representative sample of patients with
schizophrenia, nearly 36% of them had concomitant CM and
antipsychotic treatment. This prevalence rate of CM use is
somewhat lower than that observed in other commonly occurring
chronic conditions in Chinese communities [17–19]. In non-CM-
using patients, nearly 58% did not believe CM could help their
condition, suggesting that the lower prevalence of CM use in
schizophrenic population is mainly related to their negative
attitude towards this traditional remedy. Unlike patients in
Western society where a minority of them informed their doctors
of their use of alternative medicine [20,21], CM use in most
patients in this study was recommended by their psychiatrists.
However, only about one-third of patients were aware of the
Table 1. Bivariate and multivariate associations of CM use
with demographic and clinical variables in patients with
schizophrenia under antipsychotic medication.a
Variable bivariate Multivariate
n
CM use
(%) p OR (95% CI) p
Gender 0.002
Female 879 33.9 1
Male 909 41.0 1.32 (1.09–1.62) 0.006
Age, yrs 0.108
,18 92 31.5 1
18–45 1478 37.1 1.04 (0.58–1.37) 0.899
.45 218 43.1 1.17 (0.71–1.94) 0.540
Marital status 0.109
Single/divorce/widow 1004 35.9 1
Married 784 39.7 1.06 (0.86–1.32) 0.589
Education, yrs 0.391
#10 1064 36.8 1
11–13 458 40.2 1.27 (0.99–1.63) 0.062
$14 266 36.1 1.01 (0.72–1.42) 0.941
Occupation 0.645
Unemployed 368 38.9 1
Non-professional 927 37.9 0.92 (0.68–1.24) 0.568
Professional and
students
493 35.9 0.81 (0.62–1.08) 0.153
Resident areas 0.135
Urban 1120 36.2 1
Rural 668 39.8 1.48 (1.18–1.85) 0.001
Household income b 0.001
Low 330 30.6 1
Average 1242 37.9 1.56 (1.19–2.06) 0.001
High 216 45.8 2.36 (1.58–3.53)
,0.001
Diagnostic subtype 0.143
Paranoid 942 39.2 1
Non-paranoid c 846 35.7 0.89 (0.73–1.09) 0.245
Duration of the illness,
yrs
,0.001
#1 396 25.0 1
.1 1392 41.1 1.95 (1.45–2.63)
,0.001
Number of episodes ,0.001
#2 895 32.2 1
.2 893 42.9 1.14 (0.84–1.53) 0.402
Number of
hospitalization
,0.001
#2 1142 33.9 1
.2 646 44.0 1.18 (0.88–1.58) 0.270
a. CM, Chinese medicine. Data analyses were based on CM users (n = 671) with
non-CM users (n = 1117) as reference. Chi-square test was used for bivariate
analysis and binary logistic regression mode for multivariate analysis.
b. Household income was compared to local average levels.
c. Non-paranoid psychosis includes disorganized, undifferentiated, residual, and
tonic types of schizophrenia and schizoaffective disorder.
doi:10.1371/journal.pone.0017239.t001
Table 2. Bivariate and multivariate associations between
clinical outcomes and CM use in patients with schizophrenia.a
Outcomes Bivariate Multivariate
n
CM users
(%) p OR (95% CI) b p
,0.001
Unchanged 898 23.7 1
Improved 793 51.7 3.44 (2.80–4.24) ,0.001
Worse 97 49.5 3.15 (2.06–4.83) ,0.001
a. CM, Chinese medicine. Data analyses were based on CM users (n = 671) with
non-CM users (n = 1117) as reference. Chi-square test was used for bivariate
analysis and binary logistic regression for multivariate analysis.
b. Binary logistic regression analysis was adjusted for sex, resident areas,
household income, duration of illness, number of episode, and number of
hospitalization, variables significantly associated with CM use as shown in
Table 1.
doi:10.1371/journal.pone.0017239.t002
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potential risks of concomitant treatment with CM. These findings
may reflect an underestimation of both potential benefits and risks
of CM use among patients and their psychiatrists.
We found that concomitant CM use was significantly associated
with male, residence in rural areas, relatively higher household
income, longer duration of illness, and more episodes and
Table 3. Bivariate and multivariate associations of clinical outcomes with demographic and clinical variables in schizophrenic
patients in Chinese medicine and antipsychotic concomitant treatment.a
Bivariate Multivariate-IM Multivariate-WS
n IM (%) WS (%) p OR (95% CI) p OR (95% CI) p
Gender 0.344
Male 373 62.2 8.0 1 1
Female 298 59.7 6.0 0.77 (0.53–1.12) 0.173 0.55 (0.28–1.10) 0.091
Age, yrs 0.625
,18 29 72.4 6.9 1 1
18–45 548 61.1 7.3 0.76 (0.24–2.43) 0.304 0.73 (0.09–5.81) 0.325
.45 74 57.5 6.4 0.40 (0.14–1.16) 0.231 0.66 (0.10–4.19) 0.438
Marital status 0.349
Single/divorce/widow 360 58.9 6.9 1 1
Married 311 63.7 7.4 1.23 (0.83–1.82) 0.816 1.30 (0.63–2.65) 0.478
Education, yrs 0.270
#10 391 62.7 8.4 1 1
11–13 184 58.7 4.9 0.72 (0.46–1.12) 0.183 0.52 (0.21–1.24) 0.299
$14 96 59.4 6.3 0.92 (0.50–1.69) 0.476 0.90 (0.30–2.73) 0.335
Occupation 0.345
Unemployed 143 55.2 8.4 1 1
Non-professional 351 63.3 7.7 1.69 (1.03–2.78) 0.183 1.39 (0.58–3.32) 0.186
Professional/students 177 61.6 5.1 1.17 (0.68–2.02) 0.835 0.70 (0.25–1.93) 0.460
Resident areas ,0.001
Rural 266 48.9 8.2 1 1
Urban 405 69.1 5.6 4.81 (3.14–7.36) ,0.001 6.91 (3.09–15.43) ,0.001
Household income b 0.302
Low 101 56.4 11.9 1 1
Average 471 62.6 6.4 1.57 (0.74–3.29) 0.213 0.66 (0.18–2.41) 0.191
High 99 58.6 6.1 1.41 (0.82–2.42) 0.136 0.44 (0.18–1.06) 0.291
Diagnostic subtype ,0.001
Non-paranoid b 302 50.7 7.2 1 1
Paranoid 369 69.7 7.0 2.65 (1.83–3.84) ,0.001 1.89 (0.96–3.71) 0.012
Duration of illness, yrs 0.991
#1 99 60.6 7.1 1 1
.1 572 61.2 7.2 1.02 (0.56–1.84) 0.958 1.17 (0.40–3.42) 0.769
Number of episodes 0.747
#2 288 60.1 8.0 1 1
.2 383 61.9 6.5 1.13 (0.65–1.97) 0.663 0.75 (0.27–2.13) 0.594
Number of hospitalization 0.780
#2 387 61.8 7.5 1 1
.2 284 60.2 6.7 0.88 (0.51–1.52) 0.655 0.86 (0.31–2.40) 0.775
Duration of CM use, months 0.007
1–3 233 58.4 3.9 1 1
.3 438 62.6 8.9 1.35 (0.91–1.98) 0.036 3.28 (1.44–7.46) 0.005
a. CM, Chinese medicine; IM, improved; WS, worse. Data analyses were based on CM users (N = 671) who had clinical outcomes with improved (n = 410), worse (n = 48),
and unchanged (n = 213) conditions. The unchanged condition served as reference. Chi-square test was used for bivariate analysis and multinomial logistic regression
for multivariate analysis.
b. The definitions of household income and non-paranoid schizophrenia are the same as Table 1.
doi:10.1371/journal.pone.0017239.t003
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hospitalizations. These associations suggest that the men living in
rural areas may have greater positive beliefs about CM for their
illnesses. Previous studies also showed that people who had
persistent and recurrent mental-emotional problems more often
sought alternative therapies than populations with other chronic
diseases [21,22].
While it was similar in most antipsychotic treatment regimens in
CM- and non-CM-using patients, there exist significant bivariate
and multivariate associations between CM use and clinical
outcomes. Patients in CM concomitant treatment had a
significantly greater chance of improved clinical outcomes
compared to non-CM use (61.1% vs. 34.3%, OR=3.44, 95%
CI 2.80–4.24). However, a small but significant number of patients
treated concomitantly with CM had a greater risk of developing
worse outcomes (7.2% vs. 4.4%, OR=2.06, 95% CI 2.06–4.83).
These data clearly indicate that CM concomitant treatment could
produce either beneficial or adverse effects on clinical outcome,
probably depending on different combinations of CM and
antipsychotics.
Furthermore, bivariate and multivariate analyses of CM-using
subgroup revealed that both improved and worse outcomes were
significantly associated with residence in urban areas, suggesting
that patients living in urban areas may have greater impacts with
CM therapy than those in rural areas. This is likely due in part to
the fact that urban patients generally have more unconventional
and conventional treatment options compared to rural patients
[16]. This perhaps results in an increase in unpredictable positive
and negative clinical effects, as the therapeutic properties of most
CM preparations are not yet well identified. Meanwhile, the
addition of CM significantly increased the chances of improved
outcomes in paranoid patients compared to non-paranoid subtype.
Several studies have demonstrated differences in neuropsycholog-
ical character and clinical response to antipsychotic treatment
between paranoid and non-paranoid subtypes [23,24] as well as
subtype specificity of genetic profile [25,26]. Thus, the greater
chance of alteration in treatment outcomes observed in paranoid
patients may reflect a similar subtype difference in clinical effects
of CM treatment.
Our results demonstrated that exceeding 3 months of CM use is
a significant predictor for both improved and worse clinical
outcomes. This finding confirms empirical evidence, suggesting
that CM therapy of most chronic conditions requires a
considerable duration in order to achieve observable improvement
[14]. However, the finding is also consistent with those of case
studies, revealing that most nephrotoxic and hepatotoxic effects
associated with herbal medicine use are observed after 1–5 months
of intake [4,5,27]. Considering difficulties in monitoring herbal
toxicity and potential herb-drug interactions due to complex
mixtures of unknown and unidentified ingredients in CM, the
determination of an optimal length of the treatment might be a
feasible strategy in minimizing adverse and toxic effects while
maximizing beneficial effects. For this purpose, correlations
between different length of CM use and changes in pharmaco-
kinetic profile of conventional drugs may deserve to be further
determined.
We found that CM-using patients whose antipsychotic regimens
included olanzapine had significantly lower chance of improved
outcomes. Meanwhile, quetiapine and clozapine monotherapy
significantly heightened the risk of developing worse outcomes,
suggesting associations of these three atypical antipsychotics with
adverse clinical outcomes when used concomitantly with CM. On
the other hand, among seven individual CM materials identified to
be significantly associated with clinical outcomes, six were found to
be significantly associated with adverse outcomes. They were
Radix Bupleuri, Fructus Gardenia, Fructus Schisandrae, Radix
Rehmanniae, Akebia Caulis, and Semen Plantaginis. Moreover,
the concomitant treatment regimens including these herbal
materials and antipsychotics associated with adverse outcomes
accounted for nearly 60% of total identified treatment regimens in
patients with worse outcomes. These data suggest that the
heightened risk of adverse outcomes observed is closely associated
with these herbal agents in combination with antipsychotic
regimens.
As the identified herbal medicines have been well demonstrated
to have high safety profiles [28], the adverse outcomes observed
seem to be attributable to herb-drug pharmacokinetic interactions
in which the pattern of drug metabolism is altered. Despite lack of
information about the interactions between herbal and antipsy-
chotic agents, early case studies reported that ginseng combined
with phenelzine and betel nut with fluphenazine caused broad
adverse effects in schizophrenic patients [29–31]. Our recent study
of bipolar patients also found that combination treatment with the
mood stabilizer carbamazepine and an herbal preparation for 26
weeks resulted in a significantly lower level of serum carbamaz-
epine compared to carbamazepine alone, suggesting that the
Table 4. Multivariate associations between clinical outcomes
and antipsychotic medication modes in patients with
schizophrenia who were treated concomitantly with CM.a
Improved (n =410) Worse (n=48)
%
OR
(95% CI) p %
OR
(95% CI) p
The most
frequently used
antipsychotics
Risperidone 56.1 1.22
(0.86–1.75)
0.900 41.7 0.81
(0.42–1.56)
0.696
Quetiapine 19.5 0.75
(0.49–1.16)
0.463 27.1 b 1.90
(0.88–4.08)
0.013
Clozapine 20.7 1.40
(0.90–2.19)
0.542 22.9 1.29
(0.63–2.66)
0.068
Olanzapine 7.1 0.48
(0.27–0.85)
0.035 12.5 0.97
(0.37–2.54)
0.463
Phenothiazines 6.5 0.92
(0.47–1.81)
0.819 2.1 0.25
(0.03–1.95)
0.837
The most
frequently used
antipsychotic
regimens
Risperidone
alone
33.9 1.34
(0.90–1.99)
0.276 33.3 1.14
(0.56–2.31)
0.424
Quetiapine
alone b
11.7 0.69
(0.41–1.17)
0.063 27.1 b 2.16
(0.95–4.95)
0.031
Clozapine +
risperidone
6.3 1.43
(0.65–3.17)
0.527 8.3 2.63
(0.74–9.38)
0.064
Clozapine
alone
4.6 1.37
(0.60–3.12)
0.438 12.5 3.02
(0.94–9.70)
0.025
Olanzapine
alone
4.1 0.57
(0.27–1.22)
0.213 12.5 1.88
(0.66–5.34)
0.399
a. CM, Chinese medicine. Unchanged outcomes (n = 213) served as reference.
Multinomial logistical regression analysis was adjusted for resident areas,
diagnostic subtype, and duration of CM use, variables significantly associated
with clinical outcomes as shown in Table 3.
b. It is noted that all quetiapine-including treatment regimens are quetiapine
monotherapy.
doi:10.1371/journal.pone.0017239.t004
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addition of herbal medicine accelerates carbamazepine metabo-
lism and lowers its blood concentration [32]. Like carbamazepine,
most antipsychotic drugs, including clozapine, olanzapine, and
quetiapine, are metabolized as substrates for cytochrome P450s
(CYPs) [33,34]. Therefore, pharmacokinetic interactions may play
an important role in influencing clinical outcomes in patients with
Table 5. Multivariate associations of clinical outcomes with individual CMs in concomitant use with antipsychotics in
schizophrenic patients.a
Individual Chinese medicine Improved (n =410) Worse (n =48)
% OR (95% CI) p % OR (95% CI) p
Radix Glycyrrhizae (Gan-Cao) 26.8 1.59 (1.06–2.38) 0.232 12.5 0.53 (0.21–1.35) 0.181
Acorus gramineus (Shi-Chang-Pu) 17.3 1.11 (0.66–1.87) 0.699 2.1 0.11 (0.01–0.88) 0.037
Ziziphus jujuba (Suan-Zao-Ren) 14.1 0.63 (0.39–1.01) 0.056 18.8 0.83 (0.36–1.90) 0.660
Curcuma root (Yu-Jin) 13.9 1.76 (0.98–3.17) 0.058 14.6 1.84 (0.70–4.79) 0.214
Radix Angelica Sinensis (Dang-Gui) 13.9 1.03 (0.63–1.70) 0.901 8.3 0.63 (0.21–1.92) 0.422
Poria cocos (Fu-Ling) 13.2 1.30 (0.76–2.24) 0.335 12.5 1.28 (0.48–3.40) 0.620
Radix Bupleuri (Chai-Hu) 12.2 1.14 (0.68–1.93) 0.616 22.9 2.49 (1.10–5.62) 0.028
Radix Polygalae (Yuan-Zhi) 10.0 0.86 (0.50–1.49) 0.599 20.8 1.82 (0.77–4.31) 0.173
Salvia Miltrorrhiza (Dan-Shen) 9.8 0.87 (0.49–1.53) 0.625 10.4 0.92 (0.33–2.61) 0.881
Lumbricus (Di-Long) 9.8 0.95 (0.54–1.68) 0.863 4.2 0.17 (0.02–1.30) 0.088
Rhizoma Atractylodes (Bai-Zhu) 9.8 1.31 (0.69–2.47) 0.408 4.2 0.51 (0.11–2.34) 0.388
Dried tangerine peel (Chen-Pi) 9.5 1.16 (0.63–2.12) 0.635 8.3 0.94 (0.30–2.97) 0.921
Fructus Gardenia (Zhi-Zi) 8.3 1.02 (0.55–1.90) 0.947 45.8 9.16 (4.19–20.02) ,0.001
Flos Carthami (Hong-Hua) 8.3 0.99 (0.57–1.75) 0.984 4.2 0.47 (0.11–2.08) 0.318
Rhizoma Chuan Xiong (Chuan-Xiong) 7.6 0.73 (0.40–1.33) 0.306 4.2 0.38 (0.09–1.69) 0.204
Semen Persicae (Tao-Ren) 7.3 0.92 (0.49–1.75) 0.808 4.2 0.53 (0.12–2.41) 0.413
Magnolia officinalis (Hou-Po) 4.3 0.59 (0.26–1.30) 0.190 8.3 1.05 (0.31–3.52) 0.938
Fructus Schisandrae (Wu-Wei-Zi) 4.1 0.89 (0.38–2.07) 0.782 22.9 3.90 (1.42–10.73) 0.008
Radix Rehmanniae (Di-Huang) 3.4 1.22 (0.49–3.06) 0.669 12.5 3.48 (1.03–11.70) 0.044
Akebia Caulis (Mu-Tong) b 1.0 0.49 (0.12–2.04) 0.326 25.0 8.92 (2.50–31.87) ,0.001
Semen Plantaginis (Che-Qian-Zi) 0.7 1.64 (0.17–16.20) 0.671 33.3 21.10 (4.32–103.05) ,0.001
a. CM, Chinese medicine. The unchanged outcomes (n = 213) served as reference. Models were adjusted for resident areas, diagnostic subtype, and duration of CM use,
variables significantly associated with clinical outcomes as shown in Table 3.
b. Akebia Caulis includes the two species: Akebia quinata (Thunb.) Decne. and Akebia trifoliate (Thunb.) Koidz.
doi:10.1371/journal.pone.0017239.t005
Table 6. Frequency distribution of herbal and antipsychotic concomitant treatment regimens associated with adverse outcome in
schizophrenic patients.
Risperidone
alone
Quetiapine
alone a,b
Clozapine
alone a Olanzepine-including a
Risperidone
+clozapine Others
Radix Bupleuri 4 1 3 2 1 0
Fructus Gardenia 7 7 2 3 3 0
Fructus Schisandrae 4 4 2 1 0 0
Radix Rehmanniae 2 2 2 0 0 0
Akebia Caulis 4 5 1 1 1 0
Semen Plantaginis 3 7 3 3 0 0
Others c 2 0 0 1 c 0 1
Subtotal 26 26 13 11 5 1
49
Total 82
a. These antipsychotic regimens are significantly associated with adverse outcome as shown in Table 4.
b. It is noted that all quetiapine-including treatment regimens are quetiapine monotherapy.
c. Other herbal material-including regimens were not counted in subtotal regimens associated with adverse outcomes.
doi:10.1371/journal.pone.0017239.t006
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schizophrenia under concomitant treatment of herbal and
antipsychotic agents observed in the present study.
There are several limitations in the present study. First, as
patients who sought CM treatment may have distinctive
perceptions about herbal medicine, psychological or ‘‘placebo’’
factors could not be excluded. The use of structured assessment
instruments, including symptom scales and laboratory tests, should
be helpful in further clarifying treatment effects of CM therapy.
Second, since a considerable portion of CM-users were unable to
provide full information about their CM formulae, it may lead to
an underestimation of individual CMs associated with clinical
outcomes. On the other hand, due to difficulties in collecting
information about dosages of herbal and antipsychotic agents as
well as the quality of herbal preparations, these factors were not
considered in the present study. However, it should be noted that
there have been extensive reports about severe adverse events
caused by overdosing, heavy metal contaminations, and adulter-
ants with conventional drugs of herbal supplements [5,35,36], all
of which might account for the presumed adverse effects of herbal
and antipsychotic combinations. Fourth, as the majority of CM
treatments were recommended by psychiatrists to their patients,
obtaining information about psychiatrists’ attitudes and knowledge
of CM would be helpful in devising safe and effective strategies of
concomitant CM and antipsychotics in the treatment of
schizophrenia. Finally, although there are many statistically
significant results found in the study, ‘‘chance significances’’ may
not be excluded. Additional cautions should be paid when the
results are considered with reference in future studies.
In conclusion, a relatively small proportion of patients with
schizophrenia have concomitant CM and antipsychotic treatment.
Such concomitant treatment may heighten the risk of developing
worse clinical outcomes in a small number, but increase the
chance of improving treatment outcomes in a much greater
number of patients. Better identification of the concomitant herbal
and antipsychotic treatment regimens that are associated with
clinical outcomes provides useful hints for further clarifying herb-
drug pharmacokinetic interactions.
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